GLP-1 RAs are being studied [archived link] for use in many other medical conditions, including fatty liver disease, Parkinsons disease, and substance use disorders, among others
As tirzepatide has continually outperformed semaglutide in clinical trials, some wonder whether it will prove more effective as a microdosed drug
Advertisement Article continues below this ad California joined several other states in restricting an option they say is no longer affordable as they confront soaring pharmaceutical costs and steep Medicaid cuts under the Trump administration, among other financial pressures
In the long run, increased capacity should reduce shortages and (potentially) drug prices
Early post-marketing surveillance and case reports raised initial concerns, prompting extensive investigation through randomised controlled trials, observational studies, and meta-analyses
*Cost at the time of publication